Cargando…
Long-term prognostic value of longitudinal measurements of blood neurofilament levels
OBJECTIVE: To assess the long-term prognostic value of an integral of longitudinal measurements of plasma neurofilament light chain levels (NfL(long)) over 12 and 24 months vs single neurofilament light chain (NfL) measurements in patients with relapsing-remitting MS (RRMS) and its additional value...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428358/ https://www.ncbi.nlm.nih.gov/pubmed/32817406 http://dx.doi.org/10.1212/NXI.0000000000000856 |
_version_ | 1783571058078515200 |
---|---|
author | Häring, Dieter A. Kropshofer, Harald Kappos, Ludwig Cohen, Jeffrey A. Shah, Anuja Meinert, Rolf Leppert, David Tomic, Davorka Kuhle, Jens |
author_facet | Häring, Dieter A. Kropshofer, Harald Kappos, Ludwig Cohen, Jeffrey A. Shah, Anuja Meinert, Rolf Leppert, David Tomic, Davorka Kuhle, Jens |
author_sort | Häring, Dieter A. |
collection | PubMed |
description | OBJECTIVE: To assess the long-term prognostic value of an integral of longitudinal measurements of plasma neurofilament light chain levels (NfL(long)) over 12 and 24 months vs single neurofilament light chain (NfL) measurements in patients with relapsing-remitting MS (RRMS) and its additional value when combined with clinical and MRI measures. METHODS: This analysis included continuously fingolimod-treated patients with RRMS from the 24-month FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis (FREEDOMS)/12-month Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS) phase 3 trials and their long-term extension, LONGTERMS. Patients were classified into high (≥30 pg/mL, n = 110) and low (<30 pg/mL, n = 164) NfL categories based on the baseline (BL) NfL value or the geometric mean NfL(long) calculated over 12 and 24 months to predict disability-related outcomes and brain volume loss (BVL). The additional prognostic value of NfL was quantified using the area under the receiver operating characteristic (ROC) curve. RESULTS: A single high (vs low) NfL measure at BL was prognostic of a higher risk of reaching Expanded Disability Status Scale (EDSS) score ≥4 earlier (hazard ratio [HR] = 2.19; 95% CI = 1.21–3.97) and higher BVL over 120 months (difference: −1.12%; 95% CI = −2.07 to −0.17). When NfL(long) was measured over 24 months, high NfL was associated with a higher risk of reaching EDSS score ≥4 (HR = 7.91; 95% CI = 2.99–20.92), accelerated 6-month confirmed disability worsening (HR = 3.14; 95% CI = 1.38–7.11), and 20% worsening in the Timed 25-Foot Walk Test (HR = 3.05; 95% CI = 1.38–6.70). Area under the ROC curve was consistently highest in models combining NfL with clinical and MRI measures. CONCLUSIONS: NfL(long) had a higher prognostic value than single NfL assessments on long-term outcomes in RRMS. Combining it with clinical and MRI measures increased sensitivity and specificity to predict long-term disease outcomes. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that NfL(long) was more strongly associated with long-term outcomes than single NfL assessments in patients with RRMS. |
format | Online Article Text |
id | pubmed-7428358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-74283582020-08-25 Long-term prognostic value of longitudinal measurements of blood neurofilament levels Häring, Dieter A. Kropshofer, Harald Kappos, Ludwig Cohen, Jeffrey A. Shah, Anuja Meinert, Rolf Leppert, David Tomic, Davorka Kuhle, Jens Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To assess the long-term prognostic value of an integral of longitudinal measurements of plasma neurofilament light chain levels (NfL(long)) over 12 and 24 months vs single neurofilament light chain (NfL) measurements in patients with relapsing-remitting MS (RRMS) and its additional value when combined with clinical and MRI measures. METHODS: This analysis included continuously fingolimod-treated patients with RRMS from the 24-month FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis (FREEDOMS)/12-month Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS) phase 3 trials and their long-term extension, LONGTERMS. Patients were classified into high (≥30 pg/mL, n = 110) and low (<30 pg/mL, n = 164) NfL categories based on the baseline (BL) NfL value or the geometric mean NfL(long) calculated over 12 and 24 months to predict disability-related outcomes and brain volume loss (BVL). The additional prognostic value of NfL was quantified using the area under the receiver operating characteristic (ROC) curve. RESULTS: A single high (vs low) NfL measure at BL was prognostic of a higher risk of reaching Expanded Disability Status Scale (EDSS) score ≥4 earlier (hazard ratio [HR] = 2.19; 95% CI = 1.21–3.97) and higher BVL over 120 months (difference: −1.12%; 95% CI = −2.07 to −0.17). When NfL(long) was measured over 24 months, high NfL was associated with a higher risk of reaching EDSS score ≥4 (HR = 7.91; 95% CI = 2.99–20.92), accelerated 6-month confirmed disability worsening (HR = 3.14; 95% CI = 1.38–7.11), and 20% worsening in the Timed 25-Foot Walk Test (HR = 3.05; 95% CI = 1.38–6.70). Area under the ROC curve was consistently highest in models combining NfL with clinical and MRI measures. CONCLUSIONS: NfL(long) had a higher prognostic value than single NfL assessments on long-term outcomes in RRMS. Combining it with clinical and MRI measures increased sensitivity and specificity to predict long-term disease outcomes. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that NfL(long) was more strongly associated with long-term outcomes than single NfL assessments in patients with RRMS. Lippincott Williams & Wilkins 2020-08-12 /pmc/articles/PMC7428358/ /pubmed/32817406 http://dx.doi.org/10.1212/NXI.0000000000000856 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Häring, Dieter A. Kropshofer, Harald Kappos, Ludwig Cohen, Jeffrey A. Shah, Anuja Meinert, Rolf Leppert, David Tomic, Davorka Kuhle, Jens Long-term prognostic value of longitudinal measurements of blood neurofilament levels |
title | Long-term prognostic value of longitudinal measurements of blood neurofilament levels |
title_full | Long-term prognostic value of longitudinal measurements of blood neurofilament levels |
title_fullStr | Long-term prognostic value of longitudinal measurements of blood neurofilament levels |
title_full_unstemmed | Long-term prognostic value of longitudinal measurements of blood neurofilament levels |
title_short | Long-term prognostic value of longitudinal measurements of blood neurofilament levels |
title_sort | long-term prognostic value of longitudinal measurements of blood neurofilament levels |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428358/ https://www.ncbi.nlm.nih.gov/pubmed/32817406 http://dx.doi.org/10.1212/NXI.0000000000000856 |
work_keys_str_mv | AT haringdietera longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels AT kropshoferharald longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels AT kapposludwig longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels AT cohenjeffreya longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels AT shahanuja longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels AT meinertrolf longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels AT leppertdavid longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels AT tomicdavorka longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels AT kuhlejens longtermprognosticvalueoflongitudinalmeasurementsofbloodneurofilamentlevels |